NRx Pharmaceuticals (NASDAQ:NRXP) Downgraded by Wall Street Zen to Sell

Wall Street Zen downgraded shares of NRx Pharmaceuticals (NASDAQ:NRXP) from a hold rating to a sell rating in a research report released on Saturday.

Several other research firms have also commented on NRXP. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research report on Wednesday, August 5th. BTIG Research lowered their price objective on NRx Pharmaceuticals to $10.00 and set a “buy” rating for the company in a research report on Friday, August 7th. D. Boral Capital reissued a “buy” rating and set a $34.00 target price on shares of NRx Pharmaceuticals in a research note on Tuesday, May 5th. Ascendiant Capital Markets lifted their target price on NRx Pharmaceuticals from $48.00 to $49.00 and gave the company a “buy” rating in a research report on Monday, April 27th. Finally, HC Wainwright restated a “buy” rating on shares of NRx Pharmaceuticals in a research report on Monday, August 10th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $34.50.

NRx Pharmaceuticals Price Performance

Shares of NRXP stock opened at $3.27 on Friday. The firm’s 50-day moving average is $3.80 and its two-hundred day moving average is $2.95. NRx Pharmaceuticals has a 12 month low of $1.62 and a 12 month high of $5.05. The company has a market capitalization of $118.47 million, a PE ratio of -5.95 and a beta of 2.18.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its earnings results on Friday, August 14th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.07). The business had revenue of $1.10 million for the quarter, compared to the consensus estimate of $1.33 million. Sell-side analysts forecast that NRx Pharmaceuticals will post -0.3 EPS for the current year.

Institutional Trading of NRx Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Ethos Financial Group LLC raised its position in NRx Pharmaceuticals by 33.6% in the first quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock valued at $34,000 after purchasing an additional 4,000 shares during the period. State Street Corp boosted its position in shares of NRx Pharmaceuticals by 14.0% during the fourth quarter. State Street Corp now owns 86,984 shares of the company’s stock worth $236,000 after buying an additional 10,700 shares during the period. Two Sigma Investments LP boosted its position in shares of NRx Pharmaceuticals by 66.4% during the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after buying an additional 20,880 shares during the period. Geode Capital Management LLC grew its stake in shares of NRx Pharmaceuticals by 17.8% in the fourth quarter. Geode Capital Management LLC now owns 218,866 shares of the company’s stock valued at $593,000 after buying an additional 33,004 shares in the last quarter. Finally, Global Retirement Partners LLC acquired a new stake in shares of NRx Pharmaceuticals in the fourth quarter valued at $107,000. Institutional investors and hedge funds own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.